Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AWD 131-138 is a partial agonist of the GABAA receptor that acts at the benzodiazepine binding site, dose-dependently stimulating GABA currents with a threshold of 0.3-1.0 µM.1 This effect is blocked by the benzodiazepine antagonist flumazenil (Item No. 14252).1 AWD 131-138 displays a broad spectrum of anticonvulsant activity in diverse seizure and epilepsy models without a tendency toward tolerance or abuse.2,3,4 It has a superior pharmacokinetic profile in dogs vs. humans.3,5
WARNING This product is not for human or veterinary use.
1. The antiepileptic drug AWD 131-
2. Imepitoin as novel treatment option for canine idiopathic epilepsy: Pharmacokinetics, distribution, and metabolism in dogs. J. Vet. Pharmacol. Ther. 37(5), 421-434 (2015).
3. The pharmacology of imepitoin: The first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs 28(1), 29-43 (2014).
4. Evaluation of the novel antiepileptic drug, AWD 131-
5. Canine epilepsy: An underutilized model. ILAR J. 55(1), 182-186 (2014).